ATP7A copper toxicosis modifier · ATP7A-related copper accumulation · Copper toxicosis modifier ATP7A · X-linked copper accumulation modifier · Menkes gene disease modifier · Copper storage disease modifier ATP7A
This genetic variant in the ATP7A gene acts as a modifier for copper toxicosis, which is a metabolic disorder affecting the liver. It influences how copper is absorbed and stored in the body, potentially reducing the severity of copper accumulation in the liver. Because it is a modifier, it does not cause disease on its own but instead alters how another genetic condition behaves.
On its own, this genetic modifier does not cause visible symptoms. Instead, it influences the onset and severity of liver-related signs associated with copper toxicosis, such as vomiting, lethargy, and yellowing of the skin or eyes (jaundice), which typically appear in middle-aged dogs.
Management is focused on the primary copper toxicosis condition and involves lifelong therapy, including copper-chelating medications and a specialized low-copper diet. The lifetime cost of managing this metabolic condition typically ranges from 1,500 to 6,000 EUR.
Estimated range of typical treatment cost. Actual cost depends on severity, clinic and region.
More conditions affecting the General / metabolic.